GV-150013X

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C33H34N4O3
Molecular Weight	534.6481
Optical Activity	( + )
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O=C(N[C@H]1C(=O)N(CC23CC4CC(CC(C4)C2)C3)C5=CC=CC=C5N(C6=CC=CC=C6)C1=O)NC7=CC=CC=C7

InChI

InChIKey=RZERRLOTRSJIAW-NGYFYKNKSA-N

InChI=1S/C33H34N4O3/c38-30-29(35-32(40)34-25-9-3-1-4-10-25)31(39)37(26-11-5-2-6-12-26)28-14-8-7-13-27(28)36(30)21-33-18-22-15-23(19-33)17-24(16-22)20-33/h1-14,22-24,29H,15-21H2,(H2,34,35,40)/t22?,23?,24?,29-,33?/m0/s1

HIDE SMILES / InChI

Molecular Formula	C33H34N4O3
Molecular Weight	534.6481
Charge	0
Count

Stereochemistry	MIXED
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Wed Apr 02 19:47:34 GMT 2025` Edited by `admin` on `Wed Apr 02 19:47:34 GMT 2025`
Record UNII	ND6YR7V9RX
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GV-150013X

Code

English

GV-150013, (S)-

Preferred Name

English

Urea, N-phenyl-N?-[(3S)-2,3,4,5-tetrahydro-2,4-dioxo-1-phenyl-5-(tricyclo[3.3.1.1<sup>3,7</sup>]dec-1-ylmethyl)-1H-1,5-benzodiazepin-3-yl]-

Code

English

GV150013X

Code

English

(S)-1-(1-(adamantan-1-ylmethyl)-2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-benzo[b][1,4]diazepin-3-yl)-3-phenylure

Systematic Name

English

Code System Code Type Description

CAS

151386-96-8

Created by admin on Wed Apr 02 19:47:34 GMT 2025 , Edited by admin on Wed Apr 02 19:47:34 GMT 2025

PRIMARY

PUBCHEM

10369863

Created by admin on Wed Apr 02 19:47:34 GMT 2025 , Edited by admin on Wed Apr 02 19:47:34 GMT 2025

PRIMARY

FDA UNII

ND6YR7V9RX

Created by admin on Wed Apr 02 19:47:34 GMT 2025 , Edited by admin on Wed Apr 02 19:47:34 GMT 2025

PRIMARY

Related Record Type Details


					B3NY85624O

CHOLECYSTOKININ-2 RECEPTOR

TARGET->INVERSE AGONIST

Qualification:

Ki

Amount:

Related Record Type Details


					ND6YR7V9RX

GV-150013X

ACTIVE MOIETY

Comments:

Phase II clinical trials for anxiety and sleep disorders.

Amount: